new
human
immunodefici
viru
type
vaccin
approach
liveattenu
measl
viru
mv
schwarz
vaccin
strain
genet
engin
express
antigen
fusion
protein
compris
antigen
revers
transcriptas
nef
studi
assess
toxic
biodistribut
shed
profil
cynomolgu
macaqu
intramuscularli
immun
one
three
time
highest
dose
intend
clinic
use
refer
schwarz
measl
vaccin
salin
monitor
clinic
day
toxicolog
paramet
includ
local
system
clinic
sign
organ
weight
haematolog
clinic
gross
patholog
histopatholog
vaccin
well
toler
morbid
clinic
sign
gross
patholog
find
observ
mean
spleen
weight
increas
three
dose
either
vaccin
correspond
increas
number
andor
size
germin
center
like
result
immun
respons
vaccin
either
vaccin
viru
replic
preferenti
secondari
lymphoid
organ
lesser
extent
epitheliumrich
tissu
eg
intestin
urinari
bladder
trachea
liver
expect
peak
viremia
viral
rna
detect
biolog
fluid
sampl
anim
immun
either
vaccin
none
sampl
contain
infecti
viru
conclus
shed
infecti
viral
particl
identifi
cynomolgu
monkey
inject
schwarz
measl
vaccin
furthermor
toxic
effect
relat
mv
vaccin
found
vaccin
studi
develop
safe
effect
prophylact
vaccin
human
immunodefici
viru
type
global
health
prioriti
past
two
decad
signific
effort
made
develop
vaccin
among
candid
vaccin
test
larg
phase
iib
iii
clinic
trial
trial
evalu
recombin
canarypox
vector
prime
protein
boost
show
modest
efficaci
acquisit
review
mcelrath
hayn
mcmichael
et
al
although
ultim
prevent
vaccin
induc
steril
immun
would
optim
vaccin
would
reduc
viral
load
diseas
progress
induct
strong
polyfunct
cell
respons
also
prove
benefici
mcmichael
et
al
live
attenu
measl
viru
mv
vaccin
strain
wide
use
strongli
immunogen
schwarz
strain
griffin
replic
rna
virus
paramyxovirida
famili
capabl
induc
longliv
antibodi
memori
cell
respons
ovsyannikova
et
al
vandermeulen
et
al
besid
highli
efficaci
vaccin
also
recogn
safe
mv
replic
cytoplasm
integr
host
cell
genom
moreov
revers
vaccin
genom
pathogen
form
never
observ
experi
accumul
vaccin
past
year
capac
induc
cell
render
recombin
mv
vector
attract
platform
vaccin
aim
induc
cell
respons
specif
transgen
sever
vaccin
express
antigen
immunogen
preclin
demonstr
combredet
et
al
guerboi
et
al
linig
et
al
lorin
et
al
construct
vaccin
candid
use
vivo
replicationcompet
mv
vector
combredet
et
al
deriv
schwarz
vaccin
strain
gener
recombin
mv
express
antigen
fusion
protein
compris
clade
b
viral
antigen
revers
transcriptas
regulatori
protein
nef
combin
liposomebas
adjuv
system
contain
lipid
mpl
et
al
antigen
shown
induc
potent
polyfunct
cell
respons
hivseroneg
volunt
van
braeckel
et
al
conduct
studi
biodistribut
shed
singleand
repeateddos
toxic
one
three
intramuscular
im
immun
cynomolgu
macaqu
potenti
intrins
toxic
studi
well
potenti
immunemedi
toxic
result
host
respons
vaccin
result
toxic
biodistribut
profil
includ
target
organ
identifi
could
use
guid
clinic
safeti
monitor
shed
profil
crucial
determin
potenti
infecti
viral
dissemin
futur
vaccin
recipi
thu
persontoperson
transmiss
viru
biodistribut
shed
toxic
profil
vaccin
compar
either
refer
vaccin
live
attenu
monoval
schwarz
mv
vaccin
rouvax
salin
human
natur
host
mv
measl
pathogenesi
tradit
studi
nonhuman
primat
suitabl
altern
model
exist
live
attenu
mv
vaccin
gener
noninfecti
rodent
except
cotton
rat
mv
replic
restrict
lung
transgen
mice
reproduc
limit
aspect
mv
pathogenesi
de
swart
current
studi
use
mvseroneg
cynomolgu
monkey
speci
highli
sensit
mv
infect
abl
develop
patholog
lesion
clinic
symptom
compar
human
mv
infect
kobun
et
al
moreov
size
permit
administr
full
human
vaccin
dose
none
known
schwarz
strain
viru
trait
includ
viral
envelop
protein
alter
construct
vector
hypothes
toxicolog
profil
tropism
shed
capac
similar
parent
strain
repres
refer
vaccin
addit
hypothes
vaccin
virus
potenti
spread
larg
varieti
organ
attenu
mv
strain
use
receptor
ubiquit
express
human
cynomolgu
macaqu
sakurai
et
al
addit
receptor
use
wildtyp
mv
dorig
et
al
wildtyp
mv
strain
use
primarili
signal
lymphocyt
activ
molecul
express
certain
immun
cell
like
lowaffin
receptor
enter
epitheli
cell
tatsuo
et
al
watanab
et
al
result
strain
replic
predominantli
lymphoid
organ
epitheli
tissu
griffin
takeda
consequ
rouvax
expect
spread
latter
organ
tissu
also
part
bodi
mv
vector
ptmmvschw
use
construct
recombin
viru
describ
previous
combredet
et
al
vector
contain
infecti
mv
cdna
correspond
antigenom
schwarz
mv
vaccin
strain
addit
transcript
unit
atu
insert
ptmmvschw
order
subclon
fusion
protein
sequenc
describ
previous
van
braeckel
et
al
compris
subtyp
b
antigen
rt
nef
brulai
atu
contain
cloningsit
cassett
insert
copi
origin
np
intergen
region
mv
genom
region
contain
cisact
sequenc
requir
transcript
viral
p
gene
enabl
recombin
mv
express
protein
like
measl
gene
atu
introduc
plasmid
backbon
sitedirect
mutagenesi
mv
p
gene
result
plasmid
viru
rescu
plasmid
use
helper
cellbas
system
develop
institut
pasteur
briefli
helper
cell
express
polymeras
schwarz
mv
n
p
protein
cotransfect
cdna
plasmid
express
schwarz
mv
polymeras
l
subsequ
transfect
helper
cell
gentli
harvest
cocultur
cell
amplif
viru
viru
titer
determin
endpoint
titrat
vero
cell
express
cell
cultur
infecti
dose
ccid
ml
select
rout
administr
im
dose
ident
intend
use
first
clinic
trial
doselevel
repres
highest
intend
human
dose
onedos
threedos
schedul
use
threedos
schedul
repres
number
dose
use
clinic
studi
plu
one
one
millilit
vaccin
viral
titer
ccid
ml
inject
intramuscularli
refer
vaccin
commerci
schwarz
mv
vaccin
rouvax
sanofiaventi
pari
franc
use
accord
manufactur
procedur
im
administr
vaccin
dose
contain
ccid
schwarz
measl
vaccin
viru
titer
determin
assay
use
vaccin
endpoint
titrat
vero
cell
inject
administ
thigh
muscl
studi
includ
purposebr
cynomolgu
monkey
macaca
fasciculari
age
either
year
male
femal
year
sexual
matur
male
obtain
noveprim
ltd
port
loui
mauritiu
seroneg
antimv
antibodi
full
experiment
period
anim
hous
dedic
primat
unit
control
environment
condit
due
biosafeti
level
candid
vaccin
class
group
ii
hous
individu
stainless
steel
cage
level
confin
appropri
precaut
establish
studi
conduct
complianc
european
regul
regard
protect
anim
use
experiment
scientif
purpos
ethic
committe
review
studi
plan
initi
studi
studi
design
follow
guidelin
publish
european
medicin
agenc
ema
well
relev
guidelin
emea
emea
experi
perform
good
laboratori
practic
glp
condit
anim
inocul
monitor
laboratori
centr
intern
de
toxicologi
cit
evreux
franc
monkey
includ
studi
young
male
young
femal
alloc
treatment
group
tabl
anim
alloc
group
sex
use
computer
random
procedur
citox
softwar
develop
inhous
cit
evreux
franc
addit
six
sexual
matur
male
three
per
group
alloc
treatment
group
use
random
procedur
use
collect
semen
peripher
blood
mononuclear
cell
pbmc
well
select
clinic
observ
bodi
weight
bodi
temperatur
food
consumpt
treatment
includ
ccid
rouvax
ccid
vaccin
salin
administ
accord
either
onedos
schedul
inject
day
threedos
schedul
inject
day
monkey
monitor
clinic
sacrific
group
return
laboratori
stock
day
group
upon
complet
observ
period
anim
group
sedat
ketamin
hydrochlorid
lyon
franc
anesthet
thiopent
sacrif
exsanguin
necropsi
perform
two
timepoint
either
within
expect
peak
viremia
day
first
vaccin
dose
day
group
clearanc
infecti
mv
expect
occur
repres
day
third
dose
day
group
auwaert
et
al
pan
et
al
permar
et
al
singleand
repeateddos
toxic
assess
variou
time
point
tabl
shed
postmortem
analys
conduct
texcel
evri
franc
procedur
conduct
cit
anim
monitor
least
twice
daili
mortal
morbid
clinic
sign
toxic
toxicolog
paramet
includ
dermal
reaction
inject
site
bodi
weight
food
consumpt
rectal
bodi
temperatur
electrocardiographi
ophthalmolog
complet
clinic
examin
perform
pretreat
thereaft
weekli
sedat
use
electrocardiographi
ophthalmolog
occasion
weigh
done
im
administ
ketamin
hydrochlorid
h
immun
dermal
reaction
includ
edema
erythema
format
evalu
use
draiz
scale
lesion
note
reaction
persist
h
immun
evalu
daili
disappear
electrocardiograph
examin
perform
use
cardiolin
delta
plu
cardiovit
schiller
ag
baar
switzerland
standard
lead
iiii
start
determin
heart
rate
pq
qt
interv
qrscomplex
durat
lead
ii
ophthalmolog
includ
assess
pupillari
light
reflex
use
tropicamid
mydriaticum
clermontferrand
franc
examin
appendag
optic
media
fundu
indirect
ophthalmoscopi
hein
germani
anterior
segment
lens
portabl
slitlamp
biomicroscop
model
kowa
japan
peripher
blood
sampl
collect
without
sedat
differ
time
point
first
third
dose
tabl
tube
contain
edta
sodium
citrat
lithium
heparin
haematolog
coagul
paramet
blood
biochemistri
respect
haematolog
ie
erythrocyt
count
haemoglobin
hb
mean
pack
cell
volum
mean
cell
hb
concentr
mean
cell
hb
thrombocyt
leucocyt
differenti
reticulocyt
determin
advia
haematolog
analys
siemen
saintdeni
franc
leukocyt
differenti
analysi
cell
morpholog
assess
blood
smear
stain
coagul
paramet
ie
prothrombin
time
activ
partial
thromboplastin
time
fibrinogen
measur
coagul
analyz
beckman
coulter
instrument
laboratori
franc
complet
blood
biochemistri
assess
advia
chemistri
system
siemen
use
whole
blood
urinalysi
includ
volum
ph
specif
graviti
protein
glucos
keton
bilirubin
nitrit
blood
hb
urobilinogen
done
use
clinitrek
urin
chemistri
analyz
siemen
blood
sampl
assess
humor
respons
taken
prevaccin
day
antimv
humor
respons
sera
measur
use
antimv
enzymelink
immunosorb
assay
elisa
adapt
commerci
immunoassay
enzygnost
antimeasl
virusig
dadebehr
illinoi
usa
peroxidaselabel
antimonkey
immunoglobulin
ig
secondari
antibodi
rockland
pennsylvania
usa
use
assay
anim
consid
respond
seroposit
antimv
antibodi
ie
absorb
measur
nm
exceed
cutoff
valu
serum
dilut
cutoff
valu
percentil
determin
per
gender
sera
collect
prior
vaccin
serum
dilut
found
equal
sera
femal
male
monkey
respect
necropsi
organ
weigh
subject
macroscop
microscop
examin
select
organ
examin
gross
patholog
histopatholog
analys
follow
applic
european
intern
guidelin
emea
emea
select
follow
organ
weigh
adren
brain
epididymid
heart
kidney
cervic
iliac
lymph
node
liver
lung
bronchi
ovari
pituitari
gland
prostat
spleen
test
thymu
thyroid
parathyroid
uteru
ratio
organ
weight
bodi
weight
necropsi
calcul
gross
patholog
extern
surfac
bodi
orific
neck
organ
tissu
cranial
caviti
surfac
brain
spinal
cord
thorac
abdomin
pelvic
caviti
content
examin
histopatholog
examin
section
tissu
stain
haematoxylin
eosin
sampl
process
biodistribut
shed
analys
select
organ
examin
biodistribut
analys
follow
applic
european
intern
guidelin
emea
emea
biodistribut
analys
tissu
sampl
mm
dissect
rins
cold
phosphatebuff
salin
pb
snapfrozen
cryotub
liquid
nitrogen
shed
analys
select
excret
biolog
fluid
ie
semen
group
serum
urin
throat
nasal
swab
saliva
vagin
secret
faec
pbmc
collect
throat
swab
saliva
nasal
secret
vagin
secret
conserv
tube
remel
oxoid
cedex
franc
semen
faec
directli
frozen
cryotub
conserv
immedi
collect
urin
centrifug
min
pellet
resuspend
pb
store
pbmc
isol
edta
blood
sampl
gradient
centrifug
frozen
pb
obtain
serum
blood
collect
plain
tube
incub
min
room
temperatur
centrifug
min
sampl
organ
tissu
excret
biolog
fluid
use
rna
extract
mv
nspecif
quantit
revers
transcriptas
rt
pcr
analysi
rtqpcr
briefli
cdna
synthes
rna
templat
amplifi
qpcr
specif
mv
n
gene
gene
ident
vaccin
virus
use
studi
frozen
organ
sampl
homogen
use
tissu
lyser
hz
min
qiagen
valencia
ca
kept
ice
sampl
lyse
use
ml
qiazol
lysi
reagent
qiagen
frozen
pbmc
excret
biolog
fluid
directli
urin
serum
throat
swab
nasal
swab
vagin
secret
dilut
factor
semen
submit
rna
extract
faec
resuspend
pb
vv
centrifug
supernat
filter
bodi
weight
record
pretreat
day
weekli
studi
end
food
consumpt
estim
daili
day
start
throughout
studi
b
dermal
observ
inject
site
record
h
vaccin
c
perform
group
day
test
done
h
post
immun
test
day
done
sacrific
one
anim
e
blood
sampl
clinic
patholog
perform
group
f
day
day
blood
sampl
haematolog
coagul
paramet
blood
biochemistri
taken
immunis
day
sampl
taken
necropsi
g
day
day
time
point
termin
anim
group
group
respect
total
rna
extract
sampl
use
rneasi
kit
biorobot
qiagen
reagent
protocol
recommend
manufactur
briefli
lyse
sampl
ml
chloroform
homogen
left
room
temperatur
min
centrifug
min
aqueou
phase
transfer
plate
place
biorobot
automat
extract
vacuum
centrifug
ethanol
vv
ad
well
mix
sampl
place
column
rna
adsorpt
membran
three
wash
step
buffer
twice
rpe
buffer
column
centrifug
min
rna
elut
elut
buffer
rnase
free
water
store
temperatur
rt
qpcr
perform
use
agpathid
onestep
rtpcr
kit
appli
biosystem
inc
foster
citi
ca
lightcycl
softwar
version
roch
appli
scienc
forward
primer
mentmf
revers
primer
mentmr
forward
mentmp
probe
aaccggca
caccc
nfq
fluorogen
probe
locat
region
bracket
forward
revers
primer
cycl
condit
min
min
cycl
follow
min
standard
curv
rtqpcr
paramet
determin
perform
use
vitro
transcript
rna
templat
sequenc
n
gene
measl
vector
suspens
gsk
viral
titer
log
ccid
ml
log
genom
equival
geq
ml
dilut
copi
geq
use
posit
extract
control
neg
rnasednas
free
h
posit
extract
control
run
quadrupl
duplic
reaction
respect
rna
recoveri
assess
nspecif
rtqpcr
spike
type
tissu
variou
concentr
rang
presenc
rna
consid
posit
measur
exceed
limit
detect
lod
geqreact
accept
criteria
error
effici
cross
point
fulfil
lod
defin
lowest
amount
copi
detect
necessarili
quantifi
exact
valu
probabl
sampl
test
vitro
infect
immunofluoresc
assay
sampl
rtqpcr
signal
detect
either
confirm
lod
low
level
lod
submit
vitro
infect
assay
presenc
infecti
viral
particl
fluid
except
semen
consid
posit
valu
exceed
lod
ccid
well
probabl
nevertheless
assay
design
detect
one
infect
cell
propag
viru
adjac
cell
result
plaqu
form
unit
aid
presenc
agaros
cultur
medium
therefor
assum
system
abl
detect
ccid
well
probabl
detect
less
howev
occur
least
ccid
present
inoculum
order
allow
adsorbt
onto
cell
semen
valid
infect
assay
could
conduct
due
high
bacteri
contamin
vero
cell
cultur
dulbecco
modifi
eagl
medium
dmem
fetal
calf
serum
fc
mm
glutamin
seed
cell
steril
ethanol
uv
coverslip
mm
place
well
one
day
inocul
plate
seed
vero
cellswel
biolog
fluid
sampl
dilut
serum
fluid
dilut
medium
antibiot
fluid
sampl
ad
vero
cell
h
inocul
co
inoculum
remov
ml
surviv
medium
mm
antibiot
supplement
vv
lowmelt
agaros
ad
plate
incub
co
day
posit
control
vero
cell
inocul
ccid
viral
suspens
describ
dilut
dilut
medium
neg
control
vero
cell
inocul
dilut
medium
presenc
infecti
viral
particl
reveal
immunofluoresc
assay
ifa
use
antibodi
direct
measl
n
protein
accept
criteria
assay
absenc
presenc
fluoresc
respect
neg
posit
control
day
incub
cultur
medium
remov
ml
paraformaldehyd
ad
min
slide
wash
pb
incub
overnight
goat
serum
next
primari
antibodi
mous
antimvn
monoclon
antibodi
chemicon
temecula
ca
usa
dilut
goat
saponin
ad
well
min
room
temperatur
wash
twice
pb
secondari
antibodi
goat
antimous
f
jackson
immunoresearch
west
grove
pa
usa
dilut
goat
saponin
ad
well
incub
min
room
temperatur
coverslip
wash
twice
pb
rins
water
mount
slide
use
vectashield
dapi
mount
medium
vector
laboratori
peterborough
uk
inspect
fluoresc
microscop
posit
neg
check
presenc
absenc
fluoresc
respect
follow
sequenc
use
statist
analys
bodi
weight
bodi
temperatur
electrocardiographi
haematolog
blood
biochemistri
urinalysi
data
test
normal
use
kolmogorovlilliefor
test
perform
follow
logtransform
data
normal
assumpt
satisfi
assess
homogen
varianc
perform
use
bartlett
test
homogen
varianc
reject
treatment
group
compar
control
group
use
dunnett
test
case
dunn
test
appli
procedur
without
logtransform
data
perform
statist
analysi
organ
weight
use
pathdata
softwar
version
statist
signific
express
p
p
mortal
morbid
observ
group
tabl
clinic
effect
record
vaccin
group
mark
dehydr
without
diarrhoea
rouvaxtr
male
day
resolv
within
follow
day
scab
format
note
one
rouvaxtr
male
onedos
threedos
group
effect
incident
selflimit
mildtomoder
natur
therefor
consid
toxicolog
irrelev
control
group
incident
vomit
day
one
male
slight
erythema
day
one
femal
note
sex
mean
bodi
weight
vaccin
control
group
significantli
differ
remain
virtual
organ
weight
elev
absolut
rel
spleen
weight
day
male
day
gender
statist
signific
rouvaxtr
femal
chang
elev
mean
absolut
rel
weight
cervic
iliac
lymph
node
mainli
treat
male
vaccin
day
lower
absolut
rel
thymu
weight
treat
male
vaccin
day
histopatholog
increas
size
white
pulp
sex
day
day
treatment
correspond
higher
spleen
weight
increas
size
white
pulp
femal
day
increas
sizesnumb
germin
center
mandibular
lymph
node
treat
male
day
increas
sizesnumb
germin
center
mandibular
lymph
node
femal
day
mf
malefemal
inject
site
aptt
activ
partial
thromboplastin
time
ck
creatin
kinas
constant
minor
increas
day
apart
schedul
fast
day
prior
procedur
individu
food
consumpt
gener
daili
ration
across
group
day
anim
sedat
consumpt
typic
daili
ration
occasion
day
nearli
femal
group
day
two
rouvaxtr
male
fast
period
impact
bodi
weight
similar
across
control
vaccin
group
thu
consid
unrel
immun
mean
rectal
temperatur
group
vaccin
male
significantli
differ
control
group
time
point
femal
sporad
note
statist
differ
group
remain
within
rang
commonli
record
anim
age
hous
similar
experiment
condit
consequ
treatmentrel
effect
bodi
temperatur
observ
studi
treatmentrel
abnorm
qualit
quantit
electrocardiographi
paramet
although
lowamplitud
r
p
wave
highor
lowamplitud
biphas
neg
wave
note
find
isol
observ
prior
post
treatment
occur
control
immun
group
also
commonli
observ
nontreat
cynomolgu
monkey
kept
similar
laboratori
condit
statist
differ
quantit
paramet
pq
qr
qt
interv
heart
rate
record
group
sinus
arrhythmia
observ
prior
treatment
one
femal
control
group
relev
ophthalmolog
find
observ
treatment
group
two
control
femal
hypopig
fundu
note
three
observ
time
point
treatmentrel
effect
note
haematolog
blood
clinic
chemistri
urinalysi
paramet
vaccin
group
time
point
valu
control
immun
anim
gender
similar
day
mean
activ
partial
thromboplastin
time
aptt
male
slightli
shorter
control
male
ie
vs
p
observ
femal
group
treatment
group
prothrombin
time
pt
unaffect
immun
blood
biochemistri
paramet
relev
find
higher
mean
creatin
kinas
ck
activ
rouvaxtr
male
compar
control
male
ie
vs
iul
p
day
due
elev
valu
record
two
anim
evalu
humor
respons
induc
vaccin
antimv
ig
antibodi
respons
measur
sera
ten
day
singl
dose
day
respons
undetect
major
immun
anim
fig
howev
seroconvers
rate
observ
anim
threedos
rouvax
group
group
day
first
dose
day
onward
suggest
antimv
humor
respons
may
fulli
develop
day
confirm
kinet
respons
vaccin
anim
assess
potenti
releas
infecti
viral
particl
pbmc
excret
biolog
fluid
includ
serum
urin
throatand
nasal
swab
saliva
vagin
secret
semen
faec
sampl
first
test
presenc
mv
viral
sequenc
nspecif
rtqpcr
assay
sampl
viral
rna
detect
even
defin
lod
test
use
vitro
infect
assay
eight
time
point
shed
analysi
perform
mv
viral
rna
detect
day
vaccin
group
time
point
signal
anim
vaccin
group
lod
tabl
except
one
posit
result
threedos
rouvax
group
group
viral
rna
detect
lod
faec
two
male
onedos
group
urin
vagin
secret
one
femal
threedos
group
rouvax
group
viral
rna
detect
throat
secret
lod
threedos
group
faec
throat
swab
vagin
secret
serum
lod
threedos
group
nasal
secret
lod
group
pbmc
lod
threedos
group
group
matur
male
posit
result
detect
sampl
control
group
saliva
sampl
treatment
group
vitro
infect
assay
lod
ccid
well
infecti
viral
particl
recov
sampl
viral
rna
detect
accept
criteria
ie
neg
posit
control
show
respect
neg
posit
result
fulfil
potenti
presenc
viral
rna
organ
tissu
vaccin
monkey
detect
rtqpcr
specif
n
gene
gene
ident
vaccin
virus
use
studi
day
mv
viral
rna
detect
larg
number
anim
tissu
vaccin
group
tabl
confirm
expect
time
point
peak
viral
replic
anim
onedos
vaccin
group
viral
rna
mainli
detect
secondari
lymphoid
organ
lymph
node
spleen
peyer
patch
nonlymphoid
tissu
intestin
major
signal
detect
lod
lesser
extent
liver
trachea
larynx
urinari
bladder
viral
rna
also
detect
anim
lung
eye
adren
anim
vaccin
group
uret
salivari
gland
group
sever
organ
rouvax
group
importantli
viral
rna
detect
brain
cerebellum
cerebrum
spinal
cord
respect
young
anim
immun
day
sacrif
day
group
blood
sampl
taken
day
b
young
anim
immun
day
sacrif
day
group
blood
sampl
taken
day
c
sexual
matur
anim
immun
day
group
blood
sampl
taken
day
region
thalamu
hypothalamu
anim
genderdetermin
pattern
detect
day
day
third
dose
viral
rna
still
detect
spleen
lymph
node
anim
vaccin
group
also
peyer
patch
intestin
rouvax
group
low
signal
also
detect
larynx
trachea
rouvax
group
viral
rna
detect
control
time
point
necropsi
gross
patholog
organ
weight
histopatholog
necropsi
either
one
three
inject
reveal
macroscop
find
attribut
either
treatment
record
find
sporad
common
cynomolgu
monkey
therefor
consid
toxicolog
irrelev
day
mean
absolut
rel
spleen
weight
male
vaccin
group
tend
higher
control
male
without
reach
statist
signific
pia
mater
cervicallumbarthorac
lod
spleen
lod
lod
lod
sternum
bone
marrow
lod
urinari
bladder
lod
lod
detect
made
remain
organ
aorta
brain
cerebellum
cerebrum
epididymid
femor
bone
articul
heart
hypothalamu
inject
site
knee
joint
optic
nerv
oesophagu
ovari
oviduct
pituitari
gland
prostat
sciatic
nerv
semin
vesicl
skelet
muscl
spinal
cord
region
stomach
fundu
test
thalamu
thyroid
parathyroid
group
time
point
n
anim
posit
signal
tissu
sampleno
test
anim
group
posit
signal
signal
defin
limit
detect
lod
rtqpcr
assay
probabl
rna
signal
detect
lod
rna
signal
detect
number
copi
less
defin
lod
geqreact
chanc
detect
posit
signal
observ
minor
extent
femal
group
tabl
similar
effect
observ
cervic
lymph
node
iliac
lymph
node
drain
lymph
node
inject
site
thigh
slight
tendenc
higher
weight
rouvaxtr
anim
mean
thymu
weight
tend
lower
treat
male
group
control
group
possibl
due
high
absolut
rel
weight
one
control
male
group
mean
valu
respect
clear
effect
immun
observ
thymu
weight
femal
group
day
mean
absolut
rel
spleen
weight
vaccin
group
higher
control
sex
reach
statist
signific
p
rouvaxtr
femal
mean
absolut
rel
weight
cervic
iliac
lymph
node
tend
higher
group
vaccin
male
compar
control
group
high
variabl
valu
note
femal
group
mean
thymu
weight
tend
lower
group
vaccin
male
rouvaxtr
femal
compar
control
group
none
differ
group
sex
observ
either
day
necropsi
support
macroscop
observ
major
immun
anim
sacrif
day
increas
absolut
andor
rel
spleen
weight
could
directli
correl
detect
viral
rna
spleen
biodistribut
analys
increas
spleen
weight
note
anim
viral
rna
detect
spleen
convers
increas
spleen
weight
observ
anim
viral
rna
detect
spleen
microscop
enlarg
white
pulp
spleen
occasion
note
anim
sacrif
day
one
three
male
one
three
femal
treat
one
three
control
femal
enlarg
primarili
due
gener
germin
center
also
note
anim
sacrif
day
one
three
male
two
three
rouvaxtr
male
time
point
increas
size
white
pulp
andor
germin
center
necessarili
link
detect
viral
rna
spleen
addit
enlarg
observ
anim
viral
rna
detect
spleen
furthermor
minim
increas
germin
center
size
andor
number
occasion
note
mandibular
lymph
node
two
three
male
sacrif
day
although
also
seen
one
three
control
femal
sacrif
day
relationship
treatment
could
exclud
effect
rare
seen
iliac
cervic
poplit
lymph
node
higher
absolut
rel
weight
cervic
iliac
lymph
node
record
male
vaccin
group
day
correl
consist
microscop
chang
relev
microscop
chang
observ
inject
site
day
necropsi
microscop
find
occur
equal
frequenc
across
group
andor
within
normal
laboratori
rang
speci
therefor
consid
toxicolog
irrelev
moreov
effect
suggest
mv
infect
follicular
necrosi
within
hair
follicl
prolif
necrot
bronchointerstiti
pneumonia
thymu
atrophi
warthinfinkeldey
cell
within
lymph
node
spleen
found
addit
evid
subacut
scleros
panenceph
rare
syndrom
human
occur
infect
wildtyp
mv
stain
character
progress
gliosi
demyelin
neuron
loss
order
support
clinic
develop
vaccin
compar
toxicolog
biodistribut
shed
profil
candid
vaccin
parent
schwarz
vaccin
strain
use
cynomolgu
macaqu
model
addit
result
may
serv
increas
knowledg
toxic
vivo
tropism
mv
vector
vaccin
strain
focu
preclin
studi
date
eg
de
vri
et
al
lemon
et
al
myer
et
al
peng
et
al
data
show
shed
infecti
viru
observ
either
two
vaccin
furthermor
toxic
effect
relat
mv
vaccin
found
vaccin
one
three
im
inject
full
human
dose
refer
vaccin
well
toler
induc
clinic
symptom
local
system
reactogen
vaccin
viru
replic
predominantli
observ
secondari
lymphoid
organ
includ
spleen
peyer
patch
major
lymph
node
lesser
extent
epitheliumrich
tissu
includ
intestin
larynx
trachea
urinari
bladder
liver
thu
design
potenti
target
organ
intrins
toxic
vaccin
howev
gross
histopatholog
effect
indic
toxic
observ
target
organ
organ
mean
spleen
weight
increas
three
dose
either
vaccin
correspond
anim
enlarg
white
pulp
due
gener
growth
germin
center
effect
like
result
immun
activ
secondari
lymphoid
organ
vaccin
also
observ
preclin
studi
sheet
et
al
speijer
et
al
less
like
local
viru
replic
organ
caus
increas
spleen
weight
clear
relationship
increas
spleen
weight
enlarg
white
pulp
presenc
viral
rna
spleen
could
establish
observ
consid
unrel
treatment
occur
incident
without
correl
gender
similar
frequenc
control
immun
anim
occasion
reduct
food
consumpt
impact
bodi
weight
consid
indic
system
toxic
dna
plasmid
vaccin
observ
food
consumpt
data
bodi
weight
correl
toxic
find
sheet
et
al
similar
conclus
could
potenti
drawn
recombin
liveattenu
vaccin
clinic
patholog
find
treatment
group
slight
statist
signific
decreas
aptt
pt
male
day
howev
shorten
aptt
gener
littl
clinic
relev
may
associ
suboptim
sampl
collect
process
adcock
et
al
awad
et
al
therefor
consid
indic
coagul
abnorm
toxicolog
relev
also
observ
day
mean
ck
activ
rouvaxtr
male
significantli
higher
control
male
elev
ck
valu
use
marker
injuri
heart
attack
sever
muscl
breakdown
muscular
dystrophi
acut
renal
failur
lott
abbott
none
condit
observ
two
male
involv
urinalysi
show
treatmentrel
effect
either
vaccin
addit
elev
ck
activ
found
anim
previou
time
point
possibl
elev
reflect
effect
imdeliv
sedat
ophthalmolog
day
effect
commonli
seen
preclin
studi
stewart
et
al
therefor
consid
advers
reaction
treatment
cell
tropism
vaccin
wildtyp
mv
strain
larg
determin
viru
entri
tatsuo
et
al
wildtyp
mv
use
predominantli
express
activ
immun
cell
tatsuo
et
al
known
mainli
replic
lymphoid
organ
epitheli
tissu
skin
respiratori
tract
intestin
urinari
bladder
griffin
takeda
recent
studi
suggest
aerosol
infect
wildtyp
mv
initi
target
macrophag
dendrit
cell
alveolar
tissu
follow
replic
region
lymph
node
system
spread
lymphoid
organ
lemon
et
al
mv
infect
epitheli
cell
remain
larg
unclear
although
put
epitheli
receptor
recent
describ
watanab
et
al
mv
vaccin
strain
use
ubiquit
receptor
addit
receptor
use
wildtyp
mv
dorig
et
al
vaccin
strain
expect
exhibit
wider
tropism
document
previous
wildtyp
mv
griffin
lemon
et
al
takeda
howev
macaqu
infect
intratrach
aerosol
wildtyp
attenu
edmonston
tag
recombin
mv
pathogen
mv
caus
signific
viremia
widespread
distribut
attenu
mv
restrict
system
spread
rare
detect
lymphoid
tissu
de
vri
et
al
contrast
observ
current
studi
data
seem
align
studi
mice
immun
intraperiton
intraven
attenu
oncolyt
edmonston
recombin
strain
infect
cell
mainli
detect
secondari
lymphoid
organ
liver
lung
myer
et
al
peng
et
al
dispar
studi
may
explain
differ
administr
rout
mv
strain
method
mv
detect
rtqpcr
result
tissu
biolog
fluid
confirm
peak
replic
around
day
first
dose
support
studi
monkey
wildtyp
attenu
mv
strain
auwaert
et
al
pan
et
al
permar
et
al
resembl
clinic
situat
vaccineinduc
peak
known
occur
day
induc
natur
infect
take
place
day
exposur
strebel
et
al
observ
viral
clearanc
vaccin
fulli
complet
day
third
dose
sinc
viral
rna
still
detect
lymphoid
epitheliumrich
tissu
consist
earlier
report
show
mv
rna
remain
detect
monkey
month
case
pbmc
even
though
clearanc
viremia
occur
within
day
pan
et
al
addit
studi
object
assess
potenti
viru
shed
vaccin
parallel
refer
vaccin
natur
infect
mv
isol
urin
day
rash
onset
gresser
katz
viral
rna
detect
pbmc
nasopharing
specimen
day
rash
onset
riddel
et
al
known
studi
shed
attenu
mv
vector
report
detect
edmonston
viral
rna
buccal
swab
monkey
intraven
administr
myer
et
al
detect
human
urin
saliva
intraperiton
administr
galani
et
al
consist
report
detect
viral
rna
attenu
mv
vaccin
strain
human
urin
day
vaccin
rota
et
al
detect
rna
urin
day
infecti
viral
particl
mv
vaccin
rare
found
human
throat
nasopharyng
secret
one
report
case
isol
schwarz
mv
vaccin
viru
throat
swab
morfin
et
al
detect
viral
rna
vaccin
peak
viremia
sampl
throat
nasopharing
swab
none
contain
infecti
viru
lod
ccid
well
probabl
therefor
transmiss
viru
person
consid
unlik
occur
also
never
document
previous
current
measl
vaccin
immunogen
candid
vaccin
investig
detail
current
studi
studi
primar
design
assess
toxicolog
biodistribut
shed
profil
candid
vaccin
howev
immun
respons
direct
transgen
character
separ
studi
use
anim
model
mvseroneg
cynomolgu
macaqu
latter
studi
candid
vaccin
shown
induc
cell
respons
well
antibodi
respons
manuscript
prepar
conclus
viral
dissemin
observ
variou
organ
shed
infecti
viral
particl
note
toxic
effect
relat
mv
vaccin
found
follow
one
three
im
inject
clinic
relev
dose
outcom
schwarz
measl
compar
vaccin
moreov
either
vaccin
viru
replic
predominantli
secondari
lymphoid
organ
lesser
extent
epitheliumrich
tissu
thu
expect
introduct
transgen
chang
toxicolog
profil
shed
capac
tropism
parent
strain
